Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer
Our findings highlight RRBP1 as an inflammation-immune-associated gene that inhibits tumor progression and improves immunotherapy efficacy by regulating the CXCL10-CXCR3 axis in the tumor microenvironment.
Authors
- Chengquan Shen (ORCID: https://orcid.org/0000-0001-8402-2271)
- Ding Hu (ORCID: https://orcid.org/0000-0003-4907-8805)
- Ruize Qin (ORCID: https://orcid.org/0009-0004-8882-6030)
- Xinzhao Zhao
- Changxue Liu (ORCID: https://orcid.org/0009-0001-3368-6796)
- Li Cheng (ORCID: https://orcid.org/0000-0002-5043-6019)
- Huaixi Ge
- Yonghua Wang
- Haitao Niu
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013809
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00